Preview

Московский хирургический журнал

Расширенный поиск

NON-REFUTING VALUE OF LYMPHOTROPIC THERAPY FOR THE PREVENTION OF INTESTINAL COMPLICATIONS IN THE POSTOPERATIVE PERIOD IN ULCERATIVE COLITIS

https://doi.org/10.17238/issn2072-3180.2020.3.27-30

Полный текст:

Аннотация

Relevance: this article examines the definitions of lymph circulation in the intestinal mesentery system in normal conditions and in the UC model, as well as the management and treatment of patients with ulcerative colitis using lymphotropic therapy in the postoperative period. The aim of this work is to study and evaluate the non-refuting value of lymphotropic therapy in patients in the complex treatment of UC in the postoperative period.
Material and methods — in serial experiments on animals — dogs, in an experiment, we have created a model of ulcerative colitis, and at the same time, before and after the creation of the model, we studied the lymph circulation in the intestinal mesentery. Based on the results of experimental studies, in a clinical setting, lymphotropic therapy was used in the complex treatment of ulcerative colitis in the postoperative period in 54 patients. To compare the results of lymphatic therapy, a control group of 43 patients was created who received conventional conventional treatment in the postoperative period.
Results: when using lymphotropic therapy in the complex treatment of ulcerative colitis, the number of intestinal complications in the postoperative period significantly decreases and the patient's stay in the hospital is reduced.

Об авторах

Yu. S. Egamov
Department of General Surgery of Andijan State Medical Institute
Узбекистан


A. E. Ruziev
Departments of general surgery of Bukhara State Medical University
Узбекистан


S. A. Khaidarov
Department of General Surgery of Andijan State Medical Institute
Узбекистан


Список литературы

1. Adler G. Crohn’s disease and ulcerative colitis. M.: GEOTAR. Medicine, 2001, 527 p.

2. Vorobiev G.I., Khalif I.L. Nonspecific inflammatory bowel diseases. M.: Miklos, 2008, 400 р.

3. Grigorieva G.A., Meshalkina N.Yu. Crohn’s disease. M.: Medicine, 2007, 84 p.

4. Asanin Yu.Yu. et al. Maseevich index: A new approach to assessing the clinical and endoscopic activity of ulcerative colitis. Gastroenterology, 2004, No. 1, pp. 14–16. (In Russ.)

5. Poluektova E.A., Lyashenko O.S., Korolev A.V. Mechanisms that ensure the interaction of bacterial cells with the host organism and their disruption in patients with inflammatory bowel diseases. Russian journal of gastroenterology, hepatology, coloproctology, 2014, No. 5, pp. 42–53. (In Russ.)

6. Sekacheva M.I. Modern aspects of the treatment of ulcerative colitis: the results of evidence-based medicine. Consilium Medicum [Electronic resource], 2003, Vol. 5, No. 10. Access mode http://www.consiliumedicum.com/media/consilium/03_10c/18shtmi).

7. Suvorova G.N., Myakisheva Yu.V., Katorkin S.E., Andreev P.S., Davydova O.E., Lyamin A.V., Kruglov E.E., Sukhachev P.A. Histological picture and microbial landscape in ulcerative colitis. Bulletin of new medical technologies, 2018, No. 4. pp. 170–175. (In Russ.)

8. Khalif I.L. Surgical treatment and biological therapy for ulcerative colitis // Khalif I.L. Russian medical journal, 2013, No. 31, p. 1632. (In Russ.)

9. Khalif I.L. Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease): clinical presentation, diagnosis and treatment. M.: Miklos, 2008.

10. Khalif I.L. Therapeutic tactics for ulcerative colitis. Russian Journal of Gastroenterology, Hepatology and Colopractology, 2006, No. 3, pp. 58–61. (In Russ.)

11. Egamov Yu.S., Ruziev A.E., Khaidarov S.A. Endomesenteric lymphotropic therapy as a method of preventing complications in the complex treatment of ulcerative colitis in the postoperative period. Journal of New Day in Medicine, 2019, No. 3, pp. 299–303. (In Russ.)

12. Dorofeev A.É., Shvets O.V. Epidemiology and risk factors of inflammatory bowel diseases. LikSprava, 2014, No. 11, pp. 22–29.

13. Langan R.C., Gotsch P.B., Krafczyk M.A. et al. Ulcerative colitis: diagnosis and treatment. Am. Fam. Physician, 2007, 76 (9), pp. 1323–1330.

14. Marinov V. Investigation of two models of trinitrobenzenesulfonicacidnduced colitis in rats. Trakia Journal of Sciences, 2015, Vol. 13, Suppl. 2, pp. 49–54.

15. Szalai Z. et al. Novel features of tea rat model of inflammatory bowel disease based on 2,4,6-trinitrobenzenesulfonic acid-induced acute colitis. Acta Biologica Szegediensis, 2014, Vol. 58(2), pp. 127–132.


Для цитирования:


Egamov Y.S., Ruziev A.E., Khaidarov S.A. NON-REFUTING VALUE OF LYMPHOTROPIC THERAPY FOR THE PREVENTION OF INTESTINAL COMPLICATIONS IN THE POSTOPERATIVE PERIOD IN ULCERATIVE COLITIS. Московский хирургический журнал. 2020;(3):27-30. https://doi.org/10.17238/issn2072-3180.2020.3.27-30

For citation:


Egamov Yu.S., Ruziev A.E., Khaidarov S.A. NON-REFUTING VALUE OF LYMPHOTROPIC THERAPY FOR THE PREVENTION OF INTESTINAL COMPLICATIONS IN THE POSTOPERATIVE PERIOD IN ULCERATIVE COLITIS. Moscow Surgical Journal. 2020;(3):27-30. https://doi.org/10.17238/issn2072-3180.2020.3.27-30

Просмотров: 56


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-3180 (Print)